The core activity of Aphaia Pharma AG is the development and marketing of pharmaceuticals, particularly in the fields of life sciences and biotechnology. The company focuses on the research and development of innovative therapeutics and medications, particularly in the areas of microvascular medicine and the treatment of diseases such as obesity and metabolic disorders.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Oral, coated glucose formulation for targeted release in the small intestine; for the treatment of obesity, prediabetes and other metabolic disorders, currently being evaluated in Phase 2 studies.
Development of precision-driven drug formulations
Development of proprietary, precision-targeted drug formulations with coated beads for the targeted delivery of natural substances to defined segments of the gastrointestinal tract.
Clinical development in obesity
Phase 2 studies in obesity with a placebo-controlled proof-of-concept design; investigation of weight change and other parameters of metabolic diseases.
Clinical development for prediabetes prevention
Phase 2 study in prediabetes to improve glucose tolerance and to assess the potential to prevent type 2 diabetes.
Knowledge
No knowledge articles yet
Once Aphaia Pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.